RT Journal Article
SR Electronic
T1 Pegfilgrastim drastically lowered risk of febrile neutropenia in Japanese patients with thoracic malignancy receiving chemotherapy - a retrospective single institutional study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2824
DO 10.1183/13993003.congress-2018.PA2824
VO 52
IS suppl 62
A1 Takashi Iwata
A1 Aya Yamamoto
YR 2018
UL http://erj.ersjournals.com/content/52/suppl_62/PA2824.abstract
AB Introduction: Pegfilgrastim (G-Lasta®, Kyowa Hakko Kirin, Tokyo, Japan), a long acting formulation of recombinant granulocyte-colony stimulating factor, has been introduced to the Japanese market since December 2014. However, its aftermarket data upon prevention of febrile neutropenia (FN) was not found.Aims and Objectives: Our aim of this retrospective study was to examine the impact of this low-dose pegfilgrastim upon prevention of FN onset in Japanese patients with thoracic malignancy receiving chemotherapy, by comparing its frequency before and after introduction of pegfilgrastim.Methods: We retrospectively reviewed all chemotherapy lines that started from July 2012 to December 2015 in our department. 92 lines of cytotoxic chemotherapy in 74 patients were found and enrolled. These lines of chemotherapy were divided into two groups, such as before and after pegfilgrastim groups, according to the period of pegfilgrastim introduction to our institute. Various clinical profiles, onsets of G3/G4 neutropenia and FN were also investigated for each line of chemotherapy.Results: Poorer performance status (p=0.0355), previous chemotherapy (p=0.0095) and radiotherapy (p=0.0186) were significantly more frequent in after pegfilgrastim group. The risk of FN onset in after pegfilgrastim group had been reduced to the one-seventh compared with before pegfilgrastim group (p=0.0179, odds ratio 6.752) by multivariate analysis.Conclusion: Our study proved that this lowered dose of pegfilgrastim was effective to reduce FN risk in actual Japanese patients with thoracic malignancy.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2824.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).